A large network meta-analysis ranked eight GLP-1 receptor agonists for glycemic, weight, and safety outcomes in adults with ...

Albiglutide therapy as an adjunct to standard type 2 diabetes treatment reduced cardiovascular event incidence among older adults.

Albiglutide, a long-acting glucagon-like peptide-1 receptor agonist, reduces the risk of cardiovascular events among older adults with type 2 diabetes and cardiovascular disease, according to the ...

Adults with type 2 diabetes and atherosclerotic disease randomly assigned to the once-weekly GLP-1 receptor agonist albiglutide experienced a 22% reduction in risk for major adverse cardiac events ...

CV-hypertension-diabetes_G_970433292 Albiglutide is available in other countries, and this trial may serve as an impetus for its reintroduction in the United States, particularly if follow-up ...

New research constantly uncovers new diabetes drugs that are developed by biotechnology and pharmaceutical companies through several clinical trial phases.

While the GLP-1 receptor agonist albiglutide (Tanzeum) was withdrawn from the market in 2017, it has now proven to cut cardiovascular events in type 2 diabetes. In the Harmony Outcomes trial, a ...

HealthDay News — For patients with type 2 diabetes and existing cardiovascular disease, albiglutide results in fewer cardiovascular events, according to a study published online October 2 in The ...